Story · Medicine & Biotech
Summit Therapeutics Expands Ivonescimab Development Program With New Phase III HARMONi-10 Trial
1 outlet · first reported by OncoDaily on
While the FDA recently declined to approve ivonescimab in combination with chemotherapy for previously treated EGFR-mutated advanced non-small cell lung cancer (NSCLC), Summit Therapeutics continues to expand the drug’s clinical (OncoDaily)
Coverage, in order
-
Summit Therapeutics Expands Ivonescimab Development Program With New Phase III HARMONi-10 TrialWhile the FDA recently declined to approve ivonescimab in combination with chemotherapy for previously treated EGFR-mutated advanced non-small cell lung cancer (NSCLC), Summit Therapeutics continues to expand the drug’s clinical
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.